Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher ...

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...

"Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the growing population of patients with metastatic prostate cancer," said ...

Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will ...